NCT07503496 Evaluation of the Efficacy of Biobran (Rice Bran Arabinoxylan) in Supporting Breast Cancer Chemotherapy
| NCT ID | NCT07503496 |
| Status | Recruiting |
| Phase | — |
| Sponsor | China Medical University Hospital |
| Condition | Breast Cancer Stages I |
| Study Type | INTERVENTIONAL |
| Enrollment | 96 participants |
| Start Date | 2025-04-07 |
| Primary Completion | 2026-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 96 participants in total. It began in 2025-04-07 with a primary completion date of 2026-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate the potential supportive effects of rice bran arabinoxylan compound (Biobran) in patients with breast cancer receiving paclitaxel and doxorubicin chemotherapy. The study will assess chemotherapy-related side effects, quality of life, tumor size, tumor antigens, and routine blood test parameters over 24 weeks of treatment.
Eligibility Criteria
Inclusion Criteria: * Breast cancer stage I-III Exclusion Criteria: * pregnant, lactation, breast recurrence, mental disease, autoimmune disease over hte past 5 years, people who take plant or fungal polysaccharide health supplements
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07503496 clinical trial?
This trial is open to female participants only, aged 20 Years or older, up to 65 Years, studying Breast Cancer Stages I. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07503496 currently recruiting?
Yes, NCT07503496 is actively recruiting participants. Contact the research team at cklii@mail.cmu.edu.tw for enrollment information.
Where is the NCT07503496 trial being conducted?
This trial is being conducted at Taichung, Taiwan, Taichung, Taiwan.
Who is sponsoring the NCT07503496 clinical trial?
NCT07503496 is sponsored by China Medical University Hospital. The trial plans to enroll 96 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.